{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-090094","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2026-08-04T12:25:32+00:00","discovered_at":"2026-08-04T12:30:04.313689+00:00","generated_at":"2026-08-04T12:30:09.093470+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Nuvectis Pharma reports Q2 2026 results; in-licenses two late-stage assets, ciprocopan approved in China, raises $115M","bullets":["In-licensed ex-China rights to ciprocopan (NXP100) and NXP200 from Haisco; ciprocopan approved in China for PNH in July 2026.","Completed follow-on offering in July 2026 raising $115M gross proceeds, extending cash runway into 1H 2029.","Cash and equivalents $22.2M as of June 30, 2026, down from $31.6M at Dec 31, 2025.","Net loss for Q2 2026 was $7.0M vs $6.3M in Q2 2025; R&D expenses rose to $4.7M from $3.6M.","U.S. IND submission for ciprocopan expected in 4Q2026; NXP200 IND also expected in 4Q2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-090094","json":"https://secwatch.observer/filing/0001104659-26-090094.json","markdown":"https://secwatch.observer/filing/0001104659-26-090094.md","text":"https://secwatch.observer/filing/0001104659-26-090094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465926090094/0001104659-26-090094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465926090094/tm2622125d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T12:30:09.093470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}